Project Grant R44CA250885
- Federal Grant Award Summary Metastx LLC received a $399,954 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded July 1, 2025, with completion targeted for June 30, 2026. The company will develop a novel predictive model for metastatic prostate cancer by integrating epithelial-mesenchymal transition (EMT) signature markers with machine learning-based analysis and advanced imaging technologies. The project...
- The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...
- Summary The National Cancer Institute (NCI) awarded Omnecoil Instruments, Inc. a $399,995 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 2, 2025, to conduct feasibility testing of the OmneCoil System—a novel integrated endorectal magnetic resonance imaging (MRI) and in-bore biopsy platform designed to improve prostate cancer diagnosis. The deliverable is a comprehensive feasibility study demonstrating that the OmneCoil System, consisting of a...
- The National Cancer Institute (NCI) awarded Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, a $450,904 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop an innovative single-cell (phospho-)proteomics platform for analyzing the tumor microenvironment (TME). The three-year award, active from September 1, 2025 through August 31, 2028, funds the development of technology to address critical limitations in current single-cell...
- This $255,991 National Science Foundation project grant supports the development of an automated system for rapid analysis of biopsy samples by Amcyt, Inc. The system aims to increase the efficiency and accessibility of fine needle aspiration biopsy procedures through three automated processes: sample smearing, staining, and image capture. This addresses a critical need to improve biopsy analytics and potentially eliminate up to 20% of failed procedures due to sampling errors. By automating...
- Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
- Daignostx L.L.C. received a Phase I Small Business Technology Transfer (STTR) Project Grant of $306,798 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective September 1, 2025 through August 31, 2026. The award funds development of an artificial intelligence-based lymph node (LN) malignancy classification system designed to improve cancer treatment planning by accurately identifying malignant versus benign lymph nodes. The system...
- This National Cancer Institute (NCI) Project Grant award to Georgetown University, under the Cancer Biology Research program (CFDA 93.396), provides funding of $401,115 to develop a 3D bioengineered microfluidic platform (3D-BMP) to study the mechanisms of Ewing sarcoma bone metastasis. The project aims to utilize this 3D-BMP model to perform CRISPR screens and identify key genetic drivers of Ewing sarcoma's ability to metastasize to bone, a common occurrence that is associated with poor...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
3D SPATIAL BIOLOGY OF PROSTATE CANCER BIOPSIES FOR EARLIER IDENTIFICATION OF HIGH RISK PATIENTS - ABSTRACT PROSTATE CANCER IS A CURABLE DISEASE WHEN TREATED EARLY BEFORE METASTASES OCCUR. CURRENT DIAGNOSTIC METHODS STRUGGLE TO ACCURATELY PREDICT WHICH PATIENTS WILL DEVELOP METASTASES, RESULTING IN THE DEVELOPMENT OF ADVANCED, INCURABLE DISEASE IN SOME PATIENTS WHO INITIALLY PRESENT WITH LOCALIZED DISEASE. WE PROPOSE TO TAILOR THE DEVELOPMENT OF OUR 3D SPATIAL BIOLOGY PLATFORM TOWARDS PREDICTING WHICH PROSTATE CANCER PATIENTS WILL DEVELOP METASTASES. OUR 3D SPATIAL BIOLOGY PLATFORM IS THE BASIS FOR MULTIPLE PROMINENT PUBLICATIONS, HAS AN INTERNATIONAL USER BASE, AND HAS DEMONSTRATED COMPATIBILITY WITH CURRENT LABORATORY WORKFLOWS DURING OUR PHASE I AWARD STUDIES. THE SPECIFIC AIMS OF THIS PROPOSAL ARE: 1) DEVELOP AN ACCELERATED AND AUTOMATED SAMPLE PREPARATION PROCESS, 2) DEVELOP MACHINE LEARNING MODELS TO SEGMENT TISSUE STRUCTURES AND EXTRACT 3D FEATURES FOR USE IN PREDICTIVE MODELS, AND 3) CREATE A MULTIPARAMETER MODEL TO PREDICT METASTATIC RISK FROM PROSTATE BIOPSY SAMPLES. THE STUDIES IN THIS PROPOSAL WILL ACCELERATE THE WORKFLOW TO A CLINICALLY FEASIBLE TURNAROUND TIME, BUILD A PREDICTIVE MODEL, AND DEMONSTRATE THE BENEFITS OF OUR TECHNOLOGY IN A DEFINED PROSTATE CANCER PATIENT SUBPOPULATION. OUR PARTNERS IN THIS PROPOSAL (COREPLUS) CAN RAPIDLY DEPLOY THE DEVELOPED TECHNOLOGIES IN A CLINICAL LABORATORY WITH REGULATORY ACCREDITATION AND AN EXISTING REFERRAL BASE. SUCCESSFUL COMPLETION OF THIS PROJECT WILL POSITION ALPENGLOW BIOSCIENCES TOWARDS AN ADVANCED STAGE IN COMMERCIALIZATION WITH HIGH POTENTIAL FOR SUCCESS. THIS PROJECT ADDRESSES THE IMAT GOAL OF DEVELOPING SUBSTANTIALLY IMPROVED CANCER DETECTION AND RISK ASSESSMENT TECHNOLOGIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 7/1/25 | ||
| Not listed | $994.4k | 7/9/24 |